Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis

被引:19
作者
Kontogiorgis, C. [1 ]
Hadjipavlou-Litina, D. [1 ]
机构
[1] Aristotle Univ Thessaloniki, Sch Pharm, Dept Pharmaceut Chem, Thessaloniki 54124, Greece
关键词
QSAR; thromobxane synthase inhibitors; thormboxane receptor antagonists; lipophilicity; steric factors; DUAL-ACTING AGENTS; ACID-DERIVATIVES; SYNTHETASE INHIBITORS; MODULATING AGENTS; PLATELET ACTIVATION; PROSTACYCLIN MODULATORS; BIOLOGICAL-ACTIVITY; BLOOD-VESSELS; DRUG DESIGN; BIOSYNTHESIS;
D O I
10.2174/092986710792231978
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Thromboxane A(2) (TxA(2)), a bioactive metabolite of the Arachidonic acid (AA), is a potent mediator of platelet aggregation, vasoconstriction and bronchoconstriction. It plays an important role in major human diseases, such as myocardial infraction, unstable angina, pregnancy-induced hypertension and preeclampsia, thrombosis and thrombotic disorders, pulmonary hypertension, asthma, septic shock, atherosclerosis, lupus nephritis, and Raynaud's phenomenon. Thus, TxA(2) is a therapeutic target for many research groups. A number of TXA(2) receptor antagonists as well as thromboxane synthase inhibitors have been developed. In this research we review and evaluate new quantitative structure activity relationships of thromboxane synthase inhibitors and thromboxane receptor antagonists, using the C-QSAR program of Biobyte. Lipophicity, as Clog P is a significant physicochemical parameter for this biological response. CMR/MR molar refractivity as well as sterimol parameters seemed to be important as well Molecular Volume. Electronic effects with the exception of sigma Hammett's constant are not found to govern the biological activity. The derived equations will be very helpful for the design of new potent molecules.
引用
收藏
页码:3162 / 3214
页数:53
相关论文
共 104 条
[1]   QSAR study on topically acting sulfonamides incorporating GABA moieties: A molecular connectivity approach [J].
Agrawal, VK ;
Singh, J ;
Khadikar, PV ;
Supuran, CT .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (07) :2044-2051
[2]   Four-dimensional quantitative structure-activity relationship analysis of a series of interphenylene 7-oxabicycloheptane oxazole thromboxane A2 receptor antagonists [J].
Albuquerque, MG ;
Hopfinger, AJ ;
Barreiro, EJ ;
de Alencastro, RB .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1998, 38 (05) :925-938
[3]  
[Anonymous], 2003, C QSAR VERS 4 31
[4]   DESIGN OF AN ANTITHROMBOTIC ANTIHYPERTENSIVE AGENT (WY-27569) - SYNTHESIS AND EVALUATION OF A SERIES OF 2-HETEROARYL-SUBSTITUTED DIHYDROPYRIDINES [J].
ARCHIBALD, JL ;
BRADLEY, G ;
OPALKO, A ;
WARD, TJ ;
WHITE, JC ;
ENNIS, C ;
SHEPPERSON, NB .
JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (02) :646-652
[5]   Structure and expression of the murine thromboxane A2 receptor gene [J].
Båtshake, B ;
Nilsson, C ;
Sundelin, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 256 (02) :391-397
[6]   THROMBOXANE RECEPTOR ANTAGONISM COMBINED WITH THROMBOXANE SYNTHASE INHIBITION .4. 8-[[(4-CHLOROPHENYL)SULFONYL]AMINO]-4-(3-(3-PYRIDINYL)PROPYL)OCTANOIC ACID AND ANALOGS [J].
BHAGWAT, SS ;
GUDE, C ;
BOSWELL, C ;
CONTARDO, N ;
COHEN, DS ;
DOTSON, R ;
MATHIS, J ;
LEE, W ;
FURNESS, P ;
ZOGANAS, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (23) :4373-4383
[7]   The identification and characterization of oligodendrocyte thromboxane A2 receptors [J].
Blackman, SC ;
Dawson, G ;
Antonakis, K ;
Le Breton, GC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (01) :475-483
[8]  
BOCK MG, 1990, J MED CHEM, V33, P2323
[9]   TP Receptor Antagonism: A New Concept in Atherothrombosis and Stroke Prevention [J].
Chamorro, Angel .
CEREBROVASCULAR DISEASES, 2009, 27 :20-27
[10]   Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists [J].
Cimetière, B ;
Dubuffet, T ;
Muller, O ;
Descombes, JJ ;
Simonet, S ;
Laubie, M ;
Verbeuren, TJ ;
Lavielle, J .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (11) :1375-1380